For all @ co-primary end points , the sarilumab @ mg and @ mg groups demonstrated statistically significant improvements as compared with the placebo group ( ACR@ response rate at week @ , @ % , @ % , and @ % , respectively -LSB- P < @ -RSB- ; least squares mean change in HAQ DI at week @ , -@ , -@ , and -@ , respectively -LSB- P < @ -RSB- ; and mean change in SHS at week @ , @ , @ , and @ , respectively -LSB- P < @ -RSB- ) .